-
公开(公告)号：US12066431B2
公开(公告)日：2024-08-20
申请号：US17201036
申请日：2021-03-15
Applicant: Accelerated Biosciences Corp.
Inventor： Jau-Nan Lee , Tony Tung-Ying Lee , Yuta Lee
IPC: G01N33/50 , A61K35/39 , A61K35/54 , A61K39/395 , C12N5/071 , C12N5/073 , C12N5/0735 , A61K35/12
CPC classification number: G01N33/5073 , A61K35/39 , A61K35/54 , A61K39/395 , C12N5/0605 , C12N5/0606 , C12N5/0677 , A61K35/12 , C12N2500/34 , C12N2500/38 , C12N2500/44 , C12N2501/115 , C12N2506/02 , C12N2533/54
Abstract: Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
-
公开(公告)号：US20240207325A1
公开(公告)日：2024-06-27
申请号：US18554136
申请日：2022-04-08
Applicant: BIOCRINE AB
Inventor： Per-Olof Berggren , Ingo Leibiger , Barbara Leibiger
IPC: A61K35/39 , A61K38/22 , A61K38/26 , A61P3/04 , C07K14/575 , C07K14/605 , C12N5/071 , C12N15/86
CPC classification number: A61K35/39 , A61K38/2264 , A61K38/26 , A61P3/04 , C07K14/5759 , C07K14/605 , C12N5/0677 , C12N15/86 , C12N2533/50 , C12N2710/10043
Abstract: Engineered pancreatic islet organoids encoding a polypeptide not endogenously expressed in pancreatic islet cells and methods for using them to treat diseases and disorders associated with reduced or absent expression of the polypeptide are provided.
-
公开(公告)号：US20240132850A1
公开(公告)日：2024-04-25
申请号：US18381660
申请日：2023-10-18
Applicant: NANKAI UNIVERSITY
Inventor： Deling KONG , Hongmeng MA , Zhuangzhuang YANG
IPC: C12N5/071
CPC classification number: C12N5/0677 , C12N2506/45 , C12N2513/00
Abstract: Vascularized islets and their preparation method is presented. The vascularized islets are comprised of islet spheroids enclosed within a network of blood vessels. The vascular network is composed of endothelial cells surrounded by smooth muscle cells, forming a tubular vessel with branched structures. The presence of this vasculature significantly enhances the survival of the islets, improves the efficiency of pancreatic precursor cells, islet progenitor cells and R cells, and the increases the synthesis of insulin precursor C-peptide. The procedures for constructing vascularized islets are suitable for long-term in vitro culture of islets.
-
公开(公告)号：US11760977B2
公开(公告)日：2023-09-19
申请号：US16301671
申请日：2017-05-24
Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Inventor： Ronald Evans , Michael Downes , Annette Atkins , Eiji Yoshihara , Ruth Yu
CPC classification number: C12N5/0677 , A61K35/39 , G01N33/5088 , C12N2501/117 , C12N2501/16 , C12N2501/385 , C12N2501/395 , C12N2501/415 , C12N2501/727 , C12N2501/999 , C12N2502/1382 , C12N2502/28 , C12N2503/02 , C12N2506/02 , C12N2506/45 , C12N2513/00 , C12N2533/52 , C12N2533/54 , C12N2533/90 , G01N2800/04 , G01N2800/7028
Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
-
公开(公告)号：US20180119106A1
公开(公告)日：2018-05-03
申请号：US15788989
申请日：2017-10-20
Applicant: Jeffrey Millman , Jiwon Song
Inventor： Jeffrey Millman , Jiwon Song
IPC: C12N5/071 , A61F2/02 , A61K35/39 , A61K45/06 , A61L27/38 , C08F220/14 , C12N5/0775 , A61P5/50
CPC classification number: C12N5/0677 , A61F2/02 , A61F2/022 , A61F2240/001 , A61K35/39 , A61K45/06 , A61L27/3834 , A61L27/3895 , A61P5/50 , B33Y80/00 , C08F220/14 , C08F220/28 , C12N5/0662 , C12N5/0676 , C12N2506/02 , C12N2506/1369 , C12N2506/1392 , C12N2506/22 , C12N2513/00 , C12N2533/30
Abstract: Disclosed herein is a 3D-printed, biocompatible macroporous device that houses stem cell derived β-cell (SC-β cell) clusters within a degradable fibrin gel. Cluster sizes are used that avoid severe hypoxia within 3D-printed devices and a microwell-based technique is used for resizing clusters within this range. 3D-printed devices may function for at least 12 weeks, are retrievable, and maintain structural integrity.
-
公开(公告)号：US09927426B2
公开(公告)日：2018-03-27
申请号：US14840970
申请日：2015-08-31
Applicant: Accelerated BioSciences Corporation
Inventor： Jau-Nan Lee , Tony Tung-Ying Lee , Yuta Lee
IPC: A61K35/54 , A61K39/395 , G01N33/50 , C12N5/073 , C12N5/0735 , C12N5/071 , A61K35/12
CPC classification number: G01N33/5073 , A61K35/12 , A61K35/54 , A61K39/395 , C12N5/0605 , C12N5/0606 , C12N5/0677 , C12N2500/34 , C12N2500/38 , C12N2500/44 , C12N2501/115 , C12N2506/02 , C12N2533/54
Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies. Disclosed herein are methods for treating diseases, including neurodegenerative diseases, with neural stem cells differentiated from the hTS cells such as those expressing Oct4, SSEA-1, SSEA-3, and SSEA-4.
-
公开(公告)号：US20180072995A1
公开(公告)日：2018-03-15
申请号：US15654243
申请日：2017-07-19
Inventor： Toshiro Sato , Johannes C. Clevers , Meritxell Huch Ortega
IPC: C12N5/071
CPC classification number: C12N5/0671 , C12N5/0677 , C12N5/0679 , C12N5/068 , C12N2500/32 , C12N2500/38 , C12N2501/11 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/13 , C12N2501/15 , C12N2501/155 , C12N2501/335 , C12N2501/345 , C12N2501/415 , C12N2501/998 , C12N2533/90
Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids, pancreatic organoids, liver organoids, colon organoids, Barrett's Esophagus organoids, adenocarcinoma organoids and colon carcinoma organoids that are formed in the culture medium.
-
公开(公告)号：US09752124B2
公开(公告)日：2017-09-05
申请号：US13194866
申请日：2011-07-29
Applicant: Toshiro Sato , Johannes C. Clevers , Meritxell Huch Ortega
Inventor： Toshiro Sato , Johannes C. Clevers , Meritxell Huch Ortega
CPC classification number: C12N5/0671 , C12N5/0677 , C12N5/0679 , C12N5/068 , C12N2500/32 , C12N2500/38 , C12N2501/11 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/13 , C12N2501/15 , C12N2501/155 , C12N2501/335 , C12N2501/345 , C12N2501/415 , C12N2501/998 , C12N2533/90
Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids, pancreatic organoids, liver organoids, colon organoids, Barrett's Esophagus organoids, adenocarcinoma organoids and colon carcinoma organoids that are formed in the culture medium.
-
公开(公告)号：US09670462B2
公开(公告)日：2017-06-06
申请号：US12301890
申请日：2007-05-24
Applicant: Yanan Du , Rongbin Han , Hanry Yu
Inventor： Yanan Du , Rongbin Han , Hanry Yu
CPC classification number: C12N5/0677 , C12N5/0068 , C12N5/0671 , C12N2533/20 , C12N2533/30 , C12N2533/50 , C12N2533/52 , C12N2533/54
Abstract: The invention provides a surface, wherein said surface comprises (i) a polymer substrate and (ii) sugar groups and peptide groups coupled to said substrate suitable for culturing hepatocytes.
-
公开(公告)号：US20160228377A1
公开(公告)日：2016-08-11
申请号：US15022887
申请日：2014-09-19
Applicant: BETA-CELL NV
Inventor： Myriam Lea Willy Bomans , Mike De Leeuw
CPC classification number: A61K9/4816 , A01N1/0231 , A61K9/0019 , A61K9/0024 , A61K9/1271 , A61K9/5036 , A61K35/39 , A61K2035/128 , A61L27/20 , A61L27/3687 , A61L27/3804 , A61L27/54 , A61L27/58 , A61L2430/40 , C12N5/0677
Abstract: This disclosure is in the field of medical therapy; in particular, it concerns the use of encapsulated cells in cell therapy. More in particular, this disclosure relates to the second medical use of a composition comprising encapsulated cells. Even more in particular, the disclosure relates to the use of a foreign body, suitable for implantation into a subject at a predefined location, wherein the foreign body comprises cells encapsulated in high-M alginate for inducing or stimulating angiogenesis.
Abstract translation: 本公开在医疗治疗领域; 特别地，它涉及在细胞治疗中使用包封的细胞。 更具体地，本公开涉及包含封装细胞的组合物的第二医疗用途。 更具体地，本公开涉及适用于在预定位置植入受试者的异物的使用，其中异物包含用于诱导或刺激血管发生的包封在高M藻酸盐中的细胞。
